Keudell Morrison Wealth Management Invests $334,000 in Kymera Therapeutics, Inc. $KYMR

Keudell Morrison Wealth Management purchased a new stake in Kymera Therapeutics, Inc. (NASDAQ:KYMR) in the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund purchased 7,660 shares of the company’s stock, valued at approximately $334,000.

Other institutional investors have also made changes to their positions in the company. Farther Finance Advisors LLC boosted its stake in shares of Kymera Therapeutics by 642.9% in the second quarter. Farther Finance Advisors LLC now owns 624 shares of the company’s stock valued at $27,000 after buying an additional 540 shares during the period. Caitong International Asset Management Co. Ltd bought a new stake in shares of Kymera Therapeutics in the first quarter valued at approximately $68,000. KBC Group NV boosted its stake in shares of Kymera Therapeutics by 15.2% in the first quarter. KBC Group NV now owns 2,479 shares of the company’s stock valued at $68,000 after buying an additional 328 shares during the period. Mirae Asset Global Investments Co. Ltd. boosted its stake in shares of Kymera Therapeutics by 15.8% in the second quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,516 shares of the company’s stock valued at $110,000 after buying an additional 343 shares during the period. Finally, Advisors Asset Management Inc. boosted its stake in shares of Kymera Therapeutics by 81.7% in the first quarter. Advisors Asset Management Inc. now owns 4,959 shares of the company’s stock valued at $136,000 after buying an additional 2,230 shares during the period.

Kymera Therapeutics Stock Up 3.4%

NASDAQ KYMR opened at $57.90 on Friday. The company has a market capitalization of $4.14 billion, a price-to-earnings ratio of -16.69 and a beta of 2.26. Kymera Therapeutics, Inc. has a twelve month low of $19.44 and a twelve month high of $59.00. The stock has a fifty day simple moving average of $45.67 and a 200 day simple moving average of $39.39.

Kymera Therapeutics (NASDAQ:KYMR) last posted its quarterly earnings data on Monday, August 11th. The company reported ($0.95) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.83) by ($0.12). The company had revenue of $11.48 million during the quarter, compared to analyst estimates of $17.37 million. Kymera Therapeutics had a negative net margin of 616.03% and a negative return on equity of 31.60%. The business’s revenue for the quarter was down 55.1% on a year-over-year basis. During the same quarter in the previous year, the company earned ($0.58) earnings per share. Research analysts expect that Kymera Therapeutics, Inc. will post -2.79 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several equities research analysts recently issued reports on KYMR shares. Wells Fargo & Company cut their price target on Kymera Therapeutics from $57.00 to $53.00 and set an “overweight” rating for the company in a research note on Thursday, June 26th. Jefferies Financial Group set a $64.00 price target on Kymera Therapeutics and gave the company a “buy” rating in a research note on Wednesday, June 25th. The Goldman Sachs Group upgraded shares of Kymera Therapeutics to a “strong-buy” rating in a research report on Tuesday, July 15th. BTIG Research restated a “buy” rating and set a $59.00 price objective on shares of Kymera Therapeutics in a research report on Thursday, June 26th. Finally, B. Riley upgraded shares of Kymera Therapeutics to a “strong-buy” rating and set a $60.00 price objective for the company in a research report on Wednesday, July 30th. Two research analysts have rated the stock with a Strong Buy rating, seventeen have given a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $61.26.

Insiders Place Their Bets

In related news, CFO Bruce N. Jacobs sold 79,220 shares of the stock in a transaction on Wednesday, September 17th. The stock was sold at an average price of $50.00, for a total value of $3,961,000.00. Following the completion of the sale, the chief financial officer directly owned 227,409 shares in the company, valued at $11,370,450. This represents a 25.84% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CEO Nello Mainolfi sold 30,000 shares of the company’s stock in a transaction on Tuesday, September 16th. The shares were sold at an average price of $49.00, for a total transaction of $1,470,000.00. Following the sale, the chief executive officer directly owned 660,482 shares in the company, valued at $32,363,618. This trade represents a 4.34% decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 16.01% of the company’s stock.

About Kymera Therapeutics

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.